Acrimony over Amarin CEO's departure

3 April 2023

Karim Mikhail is to resign as president and chief executive of Amarin Corp (Nasdaq: AMRN), the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing.

Mr Mikhail has claimed that he is entitled to severance payments as the result of his resignation, which the company disagrees with and intends to dispute, the filing states.

Amarin is in the process of identifying a permanent replacement for Mr Mikhail, who has been in the role since August 2021, having been with the company in a senior vice president role since July of the previous year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK